Ambroxol hydrochloride: Salt form of the mucolytic agent Ambroxol

Ambroxol hydrochloride is the salt form of Ambroxol commonly used in pharmaceutical preparations, a mucus-clearing active ingredient (mucolytic/secretolytic) for the treatment of respiratory tract diseases with thick mucus. Well-known brand names are Mucosolvan, AmbroHEXAL, Ambrobeta, and numerous generics. The substance has been approved in Germany since the 1970s and is among the best-selling over-the-counter cough remedies. A detailed pillar page on the active ingredient itself can be found at /wirkstoff/ambroxol.

In everyday use, Ambroxol hydrochloride is encountered in various dosage forms: solutions, effervescent tablets, capsules, syrups for children, lozenges, and solutions for inhalation. The hydrochloride salt form ensures good water solubility and chemical stability, which is important for the aforementioned dosage forms. In the body, the salt form immediately dissociates into the active Ambroxol and chloride ion.

Mechanism of action and salt form

Ambroxol is a metabolite of bromhexine and acts secretomotorically and secretolytically. It stimulates the serous cells of the bronchial glands to produce increased amounts of thin-fluid secretion, which liquefies thick bronchial mucus. Additionally, it activates the function of ciliated epithelium and thus promotes mucociliary transport.

Besides this, Ambroxol has further pharmacological effects: it stimulates the synthesis and secretion of pulmonary surfactant in type II pneumocytes, which improves alveolar stability. This property is discussed in pediatrics for lung maturation in threatened premature birth, but has largely been superseded by antenatal glucocorticoids. At high doses, Ambroxol also has local anesthetic effects (sodium channel inhibition), which is why it is used in lozenges for sore throat.

Pharmacokinetically, Ambroxol hydrochloride is rapidly and almost completely absorbed after oral administration (bioavailability approximately 70 percent), half-life approximately 10 hours, elimination predominantly renal after hepatic conjugation.

Indications

• Acute and chronic bronchitis: with productive cough and thick mucus
• COPD (chronic obstructive pulmonary disease): as secretolytic adjunctive agent
• Bronchiectasis: liquefaction of chronic mucus
• Colds with productive cough
• Sore throat: as lozenge with local anesthetic effect
• Cystic fibrosis: off-label as secretolytic adjunctive therapy

Dosage and administration

Adults and children aged 12 years and over: 30 mg three times daily or 75 mg sustained-release once daily. Children 6 to 12 years: 15 mg two to three times daily. Children 2 to 6 years: 7.5 mg three times daily (syrup).

Inhalation: 15 mg once to twice daily via a nebulizer, especially for inpatient use in cystic fibrosis or bronchiectasis.

Administration: with or without food, adequate fluid intake, as the mucus-clearing effect requires hydration. Duration of use without medical consultation is 4 to 5 days. For persistent cough, medical evaluation is advisable.

Renal insufficiency and hepatic insufficiency: Dose adjustment needed in severe renal insufficiency, caution in severe hepatic insufficiency.

Side effects

Common: usually well tolerated. Nausea, mild stomach pain, taste disturbances, dry mouth, pruritus.

Occasional: vomiting, diarrhea, constipation, allergic skin reactions.

Rare but important: severe skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme. The EMA indicated in 2015 after safety assessment that Ambroxol and bromhexine can very rarely cause severe skin reactions. Patients should immediately discontinue use at the first sign of skin rash with mucosal involvement and seek medical help.

Important: in infants and young children, increased mucus flow from Ambroxol may overwhelm the ability to cough up secretions, so use in this age group should be medically evaluated.

Drug interactions

• Antitussives (codeine, dextromethorphan): theoretically unfavorable combination, as Ambroxol promotes coughing up and antitussives suppress it; not recommended concomitantly for productive cough
• Antibiotics (amoxicillin, cefuroxime, erythromycin): Ambroxol increases the concentration of some antibiotics in bronchial secretions, which can be used therapeutically
• Other mucolytics (acetylcysteine, carbocisteine): additive effect possible, usually not necessary to combine
• NSAIDs: theoretically additive gastric irritation, clinically of little relevance

Special notes

Pregnancy and breastfeeding: Data limited. In the first trimester, use is preferably avoided; in the second and third trimester, use may be possible after individual assessment. In breastfeeding, use is possible as only small amounts pass into breast milk.

Efficacy debate: the clinical efficacy of secretolytics such as Ambroxol is only limited established in modern Cochrane reviews. Most studies show subjective improvement in cough and sputum; clear benefit on hard endpoints such as hospitalizations or recovery duration is limited. Nevertheless, the active ingredient has been well established clinically for decades and is frequently used in practice.

Adequate hydration: the mucus-clearing effect of Ambroxol requires adequate fluid to be present. Intake of at least 1.5 to 2 liters of water per day supports the effect.

Cough as a symptom: Cough is a symptom, not a disease itself. Medical evaluation is required for fever, bloody sputum, shortness of breath, or cough lasting more than 3 weeks.

You might also be interested in

• Ambroxol, detailed pillar page on the active ingredient
• Acetylcysteine, alternative mucolytic
• Bromhexine, precursor of Ambroxol
• Dextromethorphan, cough suppressant for dry irritative cough
• Ipratropium, anticholinergic bronchodilator

Frequently asked questions

Sources

• Gelbe Liste, Ambroxol active ingredient profile
• Cochrane Reviews on mucolytics in acute bronchitis and COPD
• BfArM, Federal Institute for Drugs and Medical Devices
• EMA Safety assessment Ambroxol and Bromhexine 2015